An interventional study of GENUS in Alzheimer Disease and Family Members, sponsored by Massachusetts General Hospital. Recruiting at 2 sites in United States. Open to participants aged 55 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-18.
Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Alzheimer Disease by Massachusetts General Hospital — 9 open to participants now, 10 under way, none of them phase 3. Alzheimer Disease · Massachusetts General Hospital.
Among the 29 studies in Alzheimer Disease by Massachusetts General Hospital, this one is the 2nd largest by planned enrollment of the 25 interventional ones that give a count, is one of 4 that started in 2024, is one of 16 with no phase, and was the 19th registered.
3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →9 of the 29 studies in Alzheimer Disease by Massachusetts General Hospital are open now, in 1 country. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 55+
Massachusetts General Hospital · Sites in United States
Ages 50–80 · Healthy volunteers
Massachusetts General Hospital · Sites in United States
Ages 18–100 · Healthy volunteers
Massachusetts General Hospital · Sites in United States
Ages 40–99 · Healthy volunteers
Massachusetts General Hospital · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.
This study: 55 Years to 90 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 6 · Phase 4 1
First in 2008; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.
Median enrollment 20 across the 25 interventional studies, 129 across the 4 observational. Of the 15 that completed or were terminated, 9 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
Massachusetts General Hospital is the lead sponsor of 2,591 studies on the registry; 445 are open to participants now.
Of its 224 completed or terminated interventional studies of FDA-regulated products, 168 (75%) have results posted.
6 of the studies in Alzheimer Disease by Massachusetts General Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05881239Massachusetts General HospitalDigital Accessible Remote Olfactory Mediated Health Assessments for Preclinical AD | 2026-12-30 |
| NCT06538311Massachusetts General HospitalTranscranial Magnetic Stimulation Treatment for Alzheimer's Disease | 2027-03-31 |
| NCT05776641Massachusetts General HospitalGamma Light and Sound Stimulation to Prevent Dementia in Cognitively Normal People at Risk for Alzheimer's Disease | 2027-05 |
| NCT07236190Massachusetts General HospitalBiomarker-based Trial of NPC-1 for Alzheimer's Pathology | 2027-06 |
| NCT05904132Massachusetts General HospitalIndividual Closed-Loop Neuromodulation Therapy for Alzheimer's Disease | 2027-06 |
Add all 6 to your calendar (.ics) → With an account.
Among the 29 studies in Alzheimer Disease by Massachusetts General Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Alzheimer's disease (AD) is characterized by significant memory loss, toxic protein deposits (amyloid and tau) in the brain, and changes in the gamma frequency band on EEG. Gamma waves are important for memory, and in patients with AD, there are fewer gamma waves in the brain. The Tsai lab found that boosting gamma waves in AD mouse models using light and sound stimulation at 40Hz not only reduced amyloid and tau in the brain, but also improved memory. A light and sound device was developed for humans that stimulates the brain at 40Hz that can be used safely at home. The goal of this study is to see if using this device can prevent dementia in people who are at risk for developing Alzheimer's disease.
The investigators are recruiting participants aged 55+ with normal memory who have or had a close family member with Alzheimer's disease. 200 participants will undergo a blood test and a subset will undergo an amyloid PET scan and only 50 participants who have cerebral amyloid deposits will continue in the study. Neither the participant nor the investigators will know whether the participant is receiving sham or active stimulation. Participants will use the device for 12 months at home, for 60 minutes each day when they are awake. Participants will come to the Massachusetts General Hospital in Boston for 4-6 visits: before starting the stimulation, at 6 months, and after 12 months of usage. The participants will undergo PET scans, MRI, EEG, blood tests and memory tests and questionnaires at each visit to monitor progress. In addition, people may elect to allow for us to study their cerebral spinal fluid. Participants will also wear a "fitbit" like watch to monitor sleep and activity throughout the study. The goal of this study is to evaluate whether stimulation with our device at 40Hz will reduce AD pathology in the brain.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Concomitant medications:
Clinical conditions:
MR imaging findings such as stroke, tumor, leukoencephalopathy that could preclude meaningful analyses of clinical and imaging data in the opinion of the site PI, such as:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The device is a light and sound device that delivers light stimulation using light-emitting diodes (LED) and sound stimulation through a speaker, with a centrally-mounted tablet that plays videos for entertainment. The device will be positioned on an easel such that the tablet is eye level with the participant while they are sitting 5 feet away. The active device delivers light and sound at 40Hz rate.
Device: GENUS
The device is the same as the active device but it delivers light and sound at different frequencies.
Device: GENUS
Participants will use the GENUS light and sound device at home for 60 minutes daily for 12 months
Changes in brain amyloid deposition over the study period, as measured by PiB PET.
The investigators will evaluate changes from baseline in amyloid deposition by using Pittsburgh compound B (PiB) PET, which is a standard for AD trial biomarkers, to assess progression towards AD with active or sham treatment.
Time frame: Baseline to 12 months
Changes in brain tau deposition
The investigators will evaluate changes from baseline in tau deposition by using MK-6240 PET
Time frame: Baseline to 12 months
Changes in brain structure using structural MRI
The investigators will evaluate changes in brain structure using structural MRI. Preliminary data show prevention of brain atrophy after 3 months of GENUS as measured by ventricular dilation and hippocampal volume. Using structural MRI, the investigators will evaluate brain volume, cortical thickness and ventricular volume.
Time frame: Baseline to 12 months
Changes in brain electrical activity
The investigators will evaluate brain electrical activity using longitudinal EEG (ie, gamma band power)
Time frame: Baseline to 12 months
Changes in brain connectivity by functional MRI
The investigators will evaluate connectivity using resting state functional MRI to assess changes in brain networks (ie, default mode network).
Time frame: Baseline to 12 months
Changes to rest-activity parameters using actigraphy.
Actigraphy will be used to evaluate rest-activity parameters (ie, interdaily stability
Time frame: Baseline to 12 months
Changes in blood biomarkers of AD
Changes in Alzheimer's blood-based biomarkers (e.g. plasma Aβ42/Aβ40 ratio, Aβ42, Aβ40, p-tau, and neurofilament light) assessed by longitudinal blood sample collection
Time frame: Baseline to 12 months
Compliance of usage as measured by timestamp tracking and eye-tracking technology
The device contains both a time-counter to track 'on time' and a camera that records images for eye-tracking, to quantitatively determine compliance with looking directly at the device. This method also quantifies whether the subjects are awake for the duration of treatment. Previous work with healthy older adults and a small cohort of mild AD patients have had 90% compliance.
Time frame: Baseline to 12 months
Change from baseline in CSF levels of amyloid and tau.
Lumbar puncture and CSF collection will be optional for participants, but will be informative as to the investigator's hypothesized mechanisms of clearance.
Time frame: Baseline to 12 months
Changes in CSF flow, as measured by BOLD fMRI
The investigators will evaluate changes from baseline in CSF flow by using BOLD fMRI. CSF flow has been linked to amyloid clearance from the brain, and brain waste clearance mechanisms such as blood vessel dilation and increased glymphatic drainage are activated after 40-Hz light and sound stimulation in our preliminary mouse studies
Time frame: Baseline to 12 months
Change from baseline in integrity of white matter tracks and myelination as measured by diffusion MR imaging.
It is hypothesized that neuromodulation causes changes in synaptic plasticity. The investigators will evaluate plasticity and structural measures of connectivity using diffusion imaging techniques.
Time frame: Baseline to 12 months
Changes in performance on memory tasks, particularly those that are reliant on visual or auditory pathways, using a neuropsychological test battery.
The investigators will evaluate changes from baseline in performance on memory tasks using a comprehensive neuropsychological battery designed to evaluate pre-clinical AD populations. Preliminary data showed that 3 months of treatment in mild AD patients led to improved performance on an associative memory task.
Time frame: Baseline to 12 months
Change from baseline in gamma oscillations as measured by EEG
Magnetoencephalogram studies done in AD patients show decreases in endogenous gamma synchronization. We will measure induced gamma entrainment using the GENUS device with EEG.
Time frame: Baseline to 12 months
Change from baseline in sleep
The investigators will evaluate sleep quality using the Pittsburgh Sleep Quality Index
Time frame: Baseline to 12 months
Change from baseline in activity levels
The investigators will evaluate activity levels using actigraphy
Time frame: Baseline to 12 months
Incidence of adverse events
Adverse Events as a result of GENUS stimulation will be reported.
Time frame: Baseline to 12 months
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2024 (actual). Primary completion is estimated for May 2027, 35 months after the start.
Of 887 non-industry interventional studies with no phase under Alzheimer Disease, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's planned 35 months is above that.
Counting every sponsor, half of 964 studies reached it within 29 months; a quarter within 15 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Massachusetts General Hospital →